reference/13557783

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/13557783

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase II\|Journal Article\|Multicenter Study\|Randomized Controlled Trial\|Research Support, Non-U.S. Gov't
issn	1946-6234 1946-6242
issueIdentifier	491
publicationName	Science Translational Medicine
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_baa3ca50b8c1f8a71ac4f219a9e3bad4
bibliographicCitation	Bolognani F, Del Valle Rubido M, Squassante L, Wandel C, Derks M, Murtagh L, Sevigny J, Khwaja O, Umbricht D, Fontoura P. A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder. Sci Transl Med. 2019 May 08;11(491). doi: 10.1126/scitranslmed.aat7838. PMID: 31043521.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a5223eef3ff91c5a182e14ebe1810f5 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6003922d2bb4e31b7ac4ac6adf3e2bef http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ac13ab3e47a167a62e8e8c144e2e3acd http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d5e40e55fe0b718f92056d959c81d407 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_97e3e030b7f885462a43ba9688eaf2da http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4f8e4f314dcd2c6fe3dfa6f5a7f3c10a http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_43d7e4c12d4dc81520b610b15cab349c http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-0974-6434 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e2c5130a2013014595f618e30bac1cbd http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-3883-257X
date	2019-05-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1126/scitranslmed.aat7838 https://pubmed.ncbi.nlm.nih.gov/31043521
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/36963 https://portal.issn.org/resource/ISSN/1946-6234 https://portal.issn.org/resource/ISSN/1946-6242
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder
discusses	http://id.nlm.nih.gov/mesh/M000608279 http://id.nlm.nih.gov/mesh/M0002356 http://id.nlm.nih.gov/mesh/M0018233 http://id.nlm.nih.gov/mesh/M000735997 http://id.nlm.nih.gov/mesh/M0021911 http://id.nlm.nih.gov/mesh/M0026520 http://id.nlm.nih.gov/mesh/M0587243
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D014230Q000627 http://id.nlm.nih.gov/mesh/D001519Q000187 http://id.nlm.nih.gov/mesh/D017483Q000378 http://id.nlm.nih.gov/mesh/D000067877Q000188 http://id.nlm.nih.gov/mesh/D011725Q000627 http://id.nlm.nih.gov/mesh/D001569Q000627 http://id.nlm.nih.gov/mesh/D065092Q000627 http://id.nlm.nih.gov/mesh/D000223Q000187
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D011788 http://id.nlm.nih.gov/mesh/D001569Q000494 http://id.nlm.nih.gov/mesh/D016896 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D065092Q000494 http://id.nlm.nih.gov/mesh/D000293 http://id.nlm.nih.gov/mesh/D055815 http://id.nlm.nih.gov/mesh/D004305 http://id.nlm.nih.gov/mesh/D011725Q000494 http://id.nlm.nih.gov/mesh/D014230Q000494 http://id.nlm.nih.gov/mesh/D008297
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID46200932 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6515

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID404859062

Total number of triples: 58.